Cadrenal Therapeutics (Nasdaq: CVKD) is a late-stage biopharmaceutical company boldly challenging the status quo by innovating a new anticoagulant to elevate care for underserved patients. The company is developing the vitamin K antagonist (VKA) tecarfarin, designed to be a superior and safer anticoagulant for individuals with implanted cardiac devices or rare cardiovascular conditions. Cadrenal strives to improve outcomes and reduce major events for these patients, who lack chronic anticoagulation options besides warfarin, well-known for its prevalent side effects and cumbersome dosing. With its innovation, the company aims to unburden these patients and their healthcare providers from warfarin’s many challenges.

This Fireside Chat was recorded during the Lytham Partners Fall 2024 Investor Conference.